Director Christine A. Poon filed a Form 4 with the SEC on November 4, 2026, disclosing the exercise of a non-qualified stock option and the sale of 7,830 shares of Regeneron Pharmaceuticals, Inc. common stock on November 2, 2026.
Key Highlights
- Option exercise: Poon exercised a non-qualified stock option for 7,830 shares of common stock at an exercise price of $376.69 per share on November 2, 2026.
- Shares sold: A total of 7,830 shares were sold across six separate transactions on November 2, 2026, at volume-weighted average prices ranging from $966.74 to $971.31 per share.
- Post-transaction ownership: Following all reported transactions, Poon directly held 5,219 shares of common stock.
- Option remaining: After the exercise, the non-qualified stock option position reported in Table II stands at 0 shares, with an expiration date of January 3, 2027.
- Vesting history: According to the filing, the exercised stock option "vested in three equal annual installments, commencing one year after the date of grant."
- Exchange and ticker: The issuer is listed as NASDAQ:REGN.
Poon's November 2 Option Exercise and Share Sales at Regeneron
According to the filing, Christine A. Poon, identified as a director of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), reported a same-day exercise-and-sell transaction on November 2, 2026. Poon exercised a non-qualified stock option covering 7,830 shares at a conversion price of $376.69, bringing her directly held share count to 13,049 before any sales were executed.
The filing discloses six separate open-market sale transactions on November 2, 2026. The sales are reported at volume-weighted average prices: 218 shares at $966.74, 772 shares at $967.38, 2,499 shares at $968.58, 3,203 shares at $969.50, 937 shares at $970.51, and 201 shares at $971.31. Each footnote in the filing states that the reported price is a volume-weighted average across a specified intraday price range, and that full per-share detail is available upon request by the SEC staff, the company, or a security holder.
After all six sale transactions were completed, Poon's direct beneficial ownership in Regeneron common stock stood at 5,219 shares, according to the filing. The non-qualified stock option reported in Table II, which carried an exercise price of $376.69 and an expiration date of January 3, 2027, was fully exercised, leaving a remaining derivative position of zero shares. The filing was signed by Christine A. Poon and dated November 4, 2026.
What Was Disclosed
Director Christine A. Poon disclosed the exercise of a non-qualified stock option for 7,830 Regeneron shares at $376.69 and the subsequent sale of all 7,830 shares on November 2, 2026, leaving her with 5,219 directly held shares.




Please wait processing your request...